| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BLPH | Exit | Bellerophon Therapeutics | $0 | – | -383,955 | -100.0% | -0.03% | – |
| PTGX | Exit | Protagonist Therapeutics Inc | $0 | – | -80,929 | -100.0% | -0.11% | – |
| OBSV | Exit | Obseva SA | $0 | – | -810,264 | -100.0% | -0.62% | – |
| NXTC | Exit | Nextcure Inc | $0 | – | -119,693 | -100.0% | -1.34% | – |
| MYOV | Exit | Myovant Sciences Ltd | $0 | – | -455,255 | -100.0% | -1.40% | – |
| MRSN | Exit | Mersana Therapeutics Inc | $0 | – | -1,561,389 | -100.0% | -1.78% | – |
| MRNS | Exit | Marinus Pharmaceuticals Inc | $0 | – | -5,016,164 | -100.0% | -2.15% | – |
| ADVM | Exit | Adverum Biotechnologies Inc | $0 | – | -946,234 | -100.0% | -2.16% | – |
| KALV | Exit | Kalvista Pharmaceuticals | $0 | – | -619,905 | -100.0% | -2.19% | – |
| ISEE | Exit | Iveric Bio Inc | $0 | – | -1,699,797 | -100.0% | -2.90% | – |
| ITCI | Exit | Intra-Cellular Therapies Inc | $0 | – | -575,000 | -100.0% | -3.92% | – |
| FTSV | Exit | Forty Seven Inc | $0 | – | -516,381 | -100.0% | -4.04% | – |
| TXG | Exit | 10X Genomics Inc. | $0 | – | -300,000 | -100.0% | -4.54% | – |
| ETNB | Exit | 89Bio Inc | $0 | – | -958,765 | -100.0% | -5.00% | – |
| RLMD | Exit | Relmada Therapeutics Inc | $0 | – | -767,938 | -100.0% | -5.95% | – |
| MIST | Exit | Milestone Pharmaceuticals Inc | $0 | – | -2,066,529 | -100.0% | -6.57% | – |
| CNST | Exit | Constellation Pharmaceuticals | $0 | – | -2,516,242 | -100.0% | -23.54% | – |
| AXSM | Exit | Axsome Therapeutics Inc | $0 | – | -1,547,994 | -100.0% | -31.77% | – |
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kalvista Pharmaceuticals | 6 | Q4 2019 | 21.5% |
| Obseva SA | 6 | Q4 2019 | 15.8% |
| Constellation Pharmaceuticals | 6 | Q4 2019 | 23.5% |
| Marinus Pharmaceuticals Inc | 6 | Q4 2019 | 5.1% |
| Bellerophon Therapeutics | 6 | Q4 2019 | 1.9% |
| BioCryst Pharmaceuticals Inc | 5 | Q3 2019 | 18.0% |
| Tricida Inc | 5 | Q3 2019 | 15.0% |
| Protagonist Therapeutics Inc | 5 | Q4 2019 | 8.0% |
| Kiniksa Pharmaceuticals Ltd | 5 | Q3 2019 | 6.7% |
| Axsome Therapeutics Inc | 4 | Q4 2019 | 31.8% |
View VHCP Management III, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-22 |
| 4 | 2024-02-08 |
| 4 | 2024-02-01 |
| 4 | 2024-01-29 |
| 4 | 2024-01-24 |
| 4 | 2024-01-19 |
| 4 | 2024-01-16 |
| 4 | 2024-01-10 |
| 4 | 2024-01-05 |
| 4 | 2023-12-29 |
View VHCP Management III, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.